Mainz Biomed Registers ColoAlert in the UK

Mainz Biomed N.V., a company focused on molecular genetics diagnostics, announced the UK registration of its colorectal cancer screening test, ColoAlert. The UK’s Medicines and Healthcare products Regulatory Agency has authorized its marketing, marking a significant milestone for the company.

This follows Mainz Biomed's partnership with EDX Medical Group plc, a UK lab, aiming to widen access to DNA-based colorectal cancer screening. With approximately 44,000 cases diagnosed annually, ColoAlert offers a non-invasive screening option by detecting DNA biomarkers in stool samples.

Guido Baechler, CEO of Mainz Biomed, indicated this approval facilitates the distribution of a reliable screening tool in the UK, enhancing preventive cancer screening efforts. This move aligns with Mainz Biomed’s mission to broaden access to early cancer detection solutions, addressing a leading cause of cancer mortality globally.